Georgia Tech 87, Cent. Arkansas 68
Morgan Stanley Raises Nutanix (NASDAQ:NTNX) Price Target to $78.00
A Chinese film set during the Covid-19 pandemic won the top prizes in Taiwan's prestigious Golden Horse Awards, which saw the highest number of entries from China in recent years despite political tensions. Beijing banned its entertainers from joining Golden Horse -- dubbed the Chinese-language "Oscars" -- in 2019 after a Taiwanese director voiced support for the island's independence in an acceptance speech in 2018.
Lotto Max jackpot hits $80M for second time ever
NEW YORK--(BUSINESS WIRE)--Dec 29, 2024-- Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Better Choice Company Inc. (NYSE American: BTTR) and SRx Health Solutions Inc. is fair to Better Choice shareholders. Upon completion of the proposed transaction, Better Choice shareholders will own approximately 15% of the combined company. Halper Sadeh encourages Better Choice shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com . The investigation concerns whether Better Choice and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Better Choice shareholders; and (2) disclose all material information necessary for Better Choice shareholders to adequately assess and value the merger consideration. On behalf of Better Choice shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. View source version on businesswire.com : https://www.businesswire.com/news/home/20241229018924/en/ CONTACT: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 sadeh@halpersadeh.com zhalper@halpersadeh.com https://www.halpersadeh.com KEYWORD: NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Halper Sadeh LLC Copyright Business Wire 2024. PUB: 12/29/2024 10:47 AM/DISC: 12/29/2024 10:46 AM http://www.businesswire.com/news/home/20241229018924/en
Packers wide receiver Romeo Doubs leaves game because of concussion
Mount St. Mary's defeats Delaware State 76-66SuRo Capital ( NASDAQ:SSSS – Get Free Report ) and BlackRock MuniHoldings New York Quality Fund ( NYSE:MHN – Get Free Report ) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Risk and Volatility SuRo Capital has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, BlackRock MuniHoldings New York Quality Fund has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Profitability This table compares SuRo Capital and BlackRock MuniHoldings New York Quality Fund’s net margins, return on equity and return on assets. Analyst Ratings SuRo Capital currently has a consensus price target of $6.00, indicating a potential upside of 18.81%. Given SuRo Capital’s stronger consensus rating and higher possible upside, equities analysts clearly believe SuRo Capital is more favorable than BlackRock MuniHoldings New York Quality Fund. Earnings and Valuation This table compares SuRo Capital and BlackRock MuniHoldings New York Quality Fund”s top-line revenue, earnings per share and valuation. SuRo Capital has higher revenue and earnings than BlackRock MuniHoldings New York Quality Fund. Insider & Institutional Ownership 13.0% of SuRo Capital shares are owned by institutional investors. Comparatively, 28.2% of BlackRock MuniHoldings New York Quality Fund shares are owned by institutional investors. 6.0% of SuRo Capital shares are owned by company insiders. Comparatively, 1.0% of BlackRock MuniHoldings New York Quality Fund shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Summary SuRo Capital beats BlackRock MuniHoldings New York Quality Fund on 6 of the 10 factors compared between the two stocks. About SuRo Capital ( Get Free Report ) SuRo Capital Corp. is a business development company. The firm seeks to invest in growth capital, late stage and venture capital-backed private companies. SuRo Capital Corp. was founded in 2010 and is based in San Francisco, California with additional office in New York, New York. About BlackRock MuniHoldings New York Quality Fund ( Get Free Report ) BlackRock MuniHoldings New York Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in investment grade New York municipal obligations exempt from federal income taxes and New York State and New York City personal income taxes. BlackRock MuniHoldings New York Quality Fund, Inc. was formed on September 19, 1997 and is domiciled in United States. Receive News & Ratings for SuRo Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SuRo Capital and related companies with MarketBeat.com's FREE daily email newsletter .Packers wide receiver Romeo Doubs leaves game because of concussion
AP Trending SummaryBrief at 9:28 a.m. ESTNone
Some quotations from Jimmy Carter . We have a tendency to exalt ourselves and to dwell on the weaknesses and mistakes of others. I have come to realize that in every person there is something fine and pure and noble, along with a desire for self-fulfillment. Political and religious leaders must attempt to provide a society within which these human attributes can be nurtured and enhanced. — from 1975 book “Why Not the Best?” Javascript is required for you to be able to read premium content. Please enable it in your browser settings.In Pictures: Jimmy Carter continued campaigning long after leaving powerGabriel is a doubt for Arsenal 's huge Premier League clash with Manchester United on Wednesday. The influential Brazil centre-back won his race to be fit for Saturday's trip to West Ham after limping out of the impressive 5-1 UEFA Champions League win over Sporting CP in midweek. Once again, Gabriel showed his prowess when attacking set-pieces by heading home an early opener from Bukayo Saka's right-wing corner. Arsenal rode a five-goal first half explosion to victory against West Ham. 💥 Watch ALL FIVE of their goals ⬇️ pic.twitter.com/bmKWXsb4Oc That set in motion a frantic first half, which ended with Arsenal 5-2 in front. Not only was the interval the end of the goalscoring, it was also the end of Gabriel's participation. Speaking after the match, Mikel Arteta confirmed a recurrence of the issue that forced the 26-year-old off in Lisbon, as opposed to any side effects from being clattered by West Ham goalkeeper Lukasz Fabianski for the penalty that Saka dispatched for the Gunners' fifth goal. MORE: All the latest Arsenal news | Premier League schedule for 2024/25 | Latest Premier League top scorer rankings "It was related to the previous injury that he had in Lisbon," Arteta said. "Obviously he did great to be part of that but with the result and the niggle that he's feeling we decided to take him off." Victory moved Arsenal to within five points of Liverpool at the summit. The leaders face champions Manchester City at Anfield on Sunday. All of the title favourites have already been hit by injury problems this season and Gabriel is not Arteta's only fresh concern coming out of the West Ham game. Riccardo Calafiori hobbled off to be replaced by Oleksandr Zinchenko at left-back, while Jorginho started at the base of the midfield following late withdrawals from Mikel Merino (knee) and Thomas Partey (muscular). Nevertheless, Arteta was heartened by the performances put in by Jakub Kiwior and his other injury replacements with United's visit to Emirates Stadium on the horizon. "We had an issue with Gabby and then we had an issue with Ricci as well," he added. "Yesterday, we lost Thomas and Mikel and Myles [Lewis-Skelly], which was very bad news. "What I'm really happy about is Jakub has to come in and does really well. Oleks the same. Jorginho I thought was exceptional today. "That's the level. Every three days we're going to need everyone at their best and it's a good sign that the team can do that."
No. 7 Tennessee gives up 1st 14 points before rallying to rout Vanderbilt 36-23McCoy Global Inc. (MCB) to Issue Quarterly Dividend of $0.02 on January 15th
Bitdeer Technologies Group ( NASDAQ:BTDR – Get Free Report ) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 12,450,000 shares, an increase of 27.7% from the November 30th total of 9,750,000 shares. Based on an average daily trading volume, of 6,160,000 shares, the short-interest ratio is currently 2.0 days. Approximately 36.7% of the shares of the company are sold short. Institutional Investors Weigh In On Bitdeer Technologies Group A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Mirabella Financial Services LLP purchased a new position in Bitdeer Technologies Group during the third quarter worth $5,872,000. D1 Capital Partners L.P. acquired a new stake in shares of Bitdeer Technologies Group during the second quarter valued at $5,386,000. Marshall Wace LLP purchased a new stake in Bitdeer Technologies Group during the 2nd quarter worth about $5,074,000. Point72 Asset Management L.P. acquired a new position in Bitdeer Technologies Group in the 2nd quarter valued at about $4,617,000. Finally, Point72 Hong Kong Ltd acquired a new position in Bitdeer Technologies Group in the 2nd quarter valued at about $4,510,000. Hedge funds and other institutional investors own 22.25% of the company’s stock. Bitdeer Technologies Group Price Performance Shares of NASDAQ BTDR opened at $23.65 on Friday. The firm’s 50-day moving average is $14.03 and its two-hundred day moving average is $10.34. The company has a market capitalization of $2.65 billion, a PE ratio of -45.48 and a beta of 2.27. Bitdeer Technologies Group has a 12-month low of $5.23 and a 12-month high of $26.24. Analyst Ratings Changes Read Our Latest Report on BTDR About Bitdeer Technologies Group ( Get Free Report ) Bitdeer Technologies Group operates as a technology company for blockchain and computing. It offers hash rate sharing solutions, including Cloud hash rate and Hash rate marketplace; and a one-stop mining machine hosting solutions encompassing deployment, maintenance, and management services for efficient cryptocurrency mining; as well as mines cryptocurrencies for its own account. Read More Receive News & Ratings for Bitdeer Technologies Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bitdeer Technologies Group and related companies with MarketBeat.com's FREE daily email newsletter .
Schmidt cites Pieringer injury as reason for lossCommerce Bank Lowers Stock Position in Diamondback Energy, Inc. (NASDAQ:FANG)
None
Football fans across the country held their breathe this Saturday during the Colorado-Kansas game. That's because future NFL quarterback Shedeur Sanders took one of the worst hits we've seen all season. Javascript is required for you to be able to read premium content. Thanks for the feedback.COLLEGE PARK — Off to its best start in six years, the Maryland women’s basketball team took the court Sunday against No. 19 Michigan State looking to prove its unbeaten record was more than the result of a relatively soft early-season schedule. In their first major test in more than a month, the No. 8 Terps built a large early lead, took the Spartans’ best counterpunch and pulled it out in the end, getting key plays down the stretch — including a layup by Christina Dalce with 36 seconds left — to help secure a hard-earned 72-66 win before an announced 9,200 at Xfinity Center. “Every league game is going to be like this. It’s going to be every possession matters,” Maryland coach Brenda Frese said. “I thought we were really resilient when you talk about staying the course for 40 minutes.” “Confidence can’t be shaken when you have so much trust and love for each other, and I think we proved that tonight,” guard Shyanne Sellers said. “I think we put our best foot forward today. It’s huge ... It’s a great win for us, but we’re not done yet.” With the win, the Terps (2-0 in the Big Ten) are off to a 12-0 start for the first time since 2018, despite a roster that includes 10 newcomers and seven transfers. To match the school-record 18-0 start of 2006, however, they still have plenty of work ahead of them, with tough matchups against No. 4 Southern California and No. 5 Texas on tap over the next three weeks. “It’s one of the most competitive groups I’ve ever coached,” Frese said. “It’s not really about being undefeated. Of course, we love it. ... I think it shows the work that they’re putting in. But for us, as long as we just continue to keep our head down and work hard through this process, I think that’s where you’re seeing the results pay off. This group hates to lose, and that’s where you want to be as a coaching staff.” Maryland forward Christina Dalce celebrates with Saylor Poffenbarger against Michigan State on Sunday, Dec. 29, 2024, at Xfinity Center in College Park. (Courtesy of Maryland Athletics) Maryland guard Kaylene Smikle drives against Michigan State on Sunday, Dec. 29, 2024, at Xfinity Center in College Park. (Courtesy of Maryland Athletics) Maryland guard Bri McDaniel puts up a shot against Michigan State on Sunday. (Courtesy of Maryland Athletics) Maryland guard Shyanne Sellers drives against Michigan State on Sunday, Dec. 29, 2024, at Xfinity Center in College Park. (Courtesy of Maryland Athletics) Maryland guard Kaylene Smikle celebrates a basket against Michigan State on Sunday at Xfinity Center in College Park. Smikle scored a team-high 19 points. (Courtesy of Maryland Athletics) Maryland coach Brenda Frese waves during a game against Michigan State on Sunday, Dec. 29, 2024, at Xfinity Center in College Park. (Courtesy of Maryland Athletics) Maryland forward Christina Dalce celebrates with Saylor Poffenbarger against Michigan State on Sunday, Dec. 29, 2024, at Xfinity Center in College Park. (Courtesy of Maryland Athletics) Kaylene Smikle scored 19 points to lead four players in double figures for the Terps, who built a 37-20 lead after a pair of free throws by Bri McDaniel (12 pounds) midway through the second quarter. But Michigan State (11-2, 1-1) clawed back into it with intense half-court defense, forcing 15 second-half turnovers and scoring nine straight points to open the fourth quarter. When Spartans guard Theryn Hallock (20 points) drained a 3-pointer from the top of the key with 6:06 to play, Michigan State had tied it at 57. In desperate need of a score, the Terps turned to guard Saylor Poffenbarger, who answered with a 3-pointer of her own to break a 4:54 scoreless streak to start the fourth quarter and give her team the lead for good. “Ironically, we had a whole lesson about momentum yesterday,” Poffenbarger said. “They obviously were going on a run, and I think just getting the momentum back on our side was really important for us. I think that shot did that for us.” Almost. The Spartans still one more run in them, getting the lead to two when Jadden Simmons sank a 3-pointer with 51 seconds left. The Terps, however, were then able to close it out, with Dalce first scoring a key layup, then stealing the ball from Hallock in the paint at the other end. Teammates Sarah Te-Biasu and Sellers each hit one of two free throws to seal the win, as the Terps closed out the game with 15 of the final 24 points. All told, Michigan State shot 32% from the field, including 6 of 24 from 3-point range. “It was probably one of our better defensive efforts,” Frese said. “You could tell the will to really get stops at the defensive end.” The schedule only becomes more difficult from here, with six more opponents currently ranked in the Associated Press Top 25. There are now six other Big Ten teams in the poll. “It will be the hardest conference slate we’ve ever faced, [and] I love to be facing it with this team,” Frese said. “With 18 conference games [and] only one team is a double, every gamer matters. Now you have head-to-head if it comes down to a tiebreaker with Michigan State. ... Our players love to be in these games, in these big moments. Fortunately for us, there’s a lot more to go.” Thursday, 7 p.m. Big Ten PlusANI Pharmaceuticals, Inc. ( NASDAQ:ANIP – Get Free Report ) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average daily volume of 253,300 shares, the days-to-cover ratio is currently 9.3 days. Insider Activity at ANI Pharmaceuticals In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold 42,231 shares of company stock worth $2,434,286 in the last ninety days. 12.70% of the stock is owned by company insiders. Hedge Funds Weigh In On ANI Pharmaceuticals Several large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the last quarter. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $207,000. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $222,000. Profund Advisors LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $225,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $228,000. 76.05% of the stock is currently owned by institutional investors. ANI Pharmaceuticals Price Performance ANI Pharmaceuticals ( NASDAQ:ANIP – Get Free Report ) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the business earned $1.05 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. Research analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year. Wall Street Analyst Weigh In A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.71. Check Out Our Latest Stock Report on ANI Pharmaceuticals About ANI Pharmaceuticals ( Get Free Report ) ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. Featured Articles Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .Taiwan Semiconductor Manufacturing (NYSE:TSM) Trading Down 1.4% – What’s Next?